DURLAZA's Acquisition

DURLAZA was acquired by Espero Pharmaceuticals on February 07, 2017.

DURLAZA is an FDA-approved and commercially available prescription 24-hour extended-release aspirin capsule, indicated for the secondary treatment of stroke and acute cardiac events.…

Articles about DURLAZA's Acquisition: